Request PDF on ResearchGate | On Feb 1, , Hugo Donato and others published Tratamiento con eritropoyetina humana recombinante. Se demostró que el tratamiento con eritropoyetina humana recombinante (EPO rHu) en pacientes en diálisis es altamente efectivo en cuanto a la corrección de. Eritropoyetina humana recombinante para la anemia de la insuficiencia renal crónica en pacientes en prediálisis. This is not the most recent version of this.
|Published (Last):||7 February 2008|
|PDF File Size:||18.29 Mb|
|ePub File Size:||10.28 Mb|
|Price:||Free* [*Free Regsitration Required]|
Population pharmacokinetics of darbepoetin alfa in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration. Balkan endemic nephropathy, Human recombinant erythropoietin, Pharmacokinetics. Pavlovic-Kentera Eritroloyetina, Djukanovic Lj. The Ethics Committee of the Clinical Center of Serbia evaluated and approved the study and the participants gave informed consent. Statistical analysis The results were expressed as mean values with standard deviations.
After beta-Epo administration plasma Epo slowly increased and C max was achieved after Analysis of covariance ANCOVA was used to adjust these differences for patient characteristics that differed between groups: Kidney Int Suppl ; We cannot confirm the completeness, accuracy and currency of the content. Therefore, not only the distribution by itself, but also the process of elimination and interaction directly with the Epo receptor on the red blood cell surface play an important role in increasing the values of Vd for Epo in comparison to its physiological distribution limited to extravascular space in the body.
The prospective clinical study was performed according to good clinical practice and in accordance with the Declaration of Helsinki in three clinical centers. By clicking Subscribe, I agree to the Drugs. Erythropoietin and anemia in the progression of Balkan endemic nephropathy and other renal diseases. Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: For pharmacokinetic analysis the predose plasma level of Epo was subtracted from all postdose levels of Epo for each patient.
Eritropoyetina Humana Recombinante –
This work was conducted as a part of projects No and funded by the Ministry of Science, Education and Technological Development, Belgrade, Republic of Serbia. However, for protein and peptide drugs, dependency on active tissue uptake, binding to intra- and extravascular proteins can substantially increase the value of Vd.
A number of pharmacokinetic studies of ESA have been published, but comparison between them is difficult due to numerous methodological differences. Available for Android and iOS devices. Subscribe to free Drugs. Ciba Foundation Study Group No. Balkan endemic nephropathy BEN hemodialysis patients require a higher dose of recombinant human erythropoietin for maintaining target hemoglobin level than patients with other kidney diseases.
Erythropoietin is reported as an ingredient of Eritropoyetina Humana Recombinante in the following countries:. The last beta-Epo dose prior to pharmacokinetics blood samplingwas omitted in all patients but recontinued at the first hemodialysis session after the study with the dose used before. Inflammation and its impact on anaemia in chronic kidney disease: Noncompartmental pharmacokinetic analysis using Kinetica software Thermo Scientific, ver.
Eritropoyetina Humana Recombinante Delta –
However, the influence of ESA pharmacokinetics on hematopoietic response has not been sufficiently investigated. Br J Clin Pharmacol ; The dose of beta-Epo was adjusted to attain the hemoglobin target range defined by European best practice guidelines for the management of anemia in patients with chronic renal failure Conflicts of interest The authors declare that they have no conflicts of interest related to the contents of this article.
Results of laboratory analyses in examined patients CRP: A total of 24 subjects was selected from the population of hemodialysis patients according to the following inclusion criteria: To view content sources and attributions, please refer to our editorial policy.
The study involved 24 hemodialysis patients, 10 patients with BEN and 14 with other kidney diseases, selected from 96 patients 40 BEN and 56 others who met the inclusion criteria. Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein NESP.
recombinnte It seems most likely that both native Epo and recombinant drugs are degraded following receptor-mediated uptake, mainly in the bone marrow.
We comply with the HONcode standard for trustworthy health information – verify here. A number of factors may contribute to insufficient hematopoietic response to ESAs: These findings need to be confirmed in a well-controlled study with a larger sample size in order to establish population pharmacokinetics of beta-Epo in BEN patients, to evaluate the effects of revombinante factors on the disposition kinetics of beta-Epo and to find potential predictive factors for dosage individualization.
Predialysis serum creatinine and PTH concentrations were significantly lower, and serum calcium concentration was significantly higher in the BEN than in the non-BEN group. Eur J Clin Pharmacol ; The main limitation of our study was the small number of patients in each group, and they were not matched in age. To view content sources and attributions, please refer to our editorial policy. El nivel de EPO en plasma previo a la dosis se sustrajo de todos los niveles que recombnante obtuvieron tras administrarla.
Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers. Today Balkan endemic nephropathy is a disease of the elderly with a good prognosis. This means it eriropoyetina still under development and may contain inaccuracies.
Eritropoyetina Humana Recombinante Delta
Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Nonerythropoietin receptor-mediated pathways may play a major role. Subscribe to free Drugs.
Renal Injury from Drugs and Chemicals, third edition. When adjusted these differences remained statistically significant 0.
Prevalence and predictors recombnante epoetin hyporesponsiveness in chronic kidney disease patients. Further information Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Methods Study design and patients The prospective clinical study was recombinanfe according to good clinical practice and in accordance with the Declaration of Helsinki in three clinical centers.